CLAIMS

1. (+)-5-(3,4-Difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.

2. A pharmaceutical containing as an active ingredient the compound according to claim 1 or a salt thereof .

3. The pharmaceutical according to claim 2, substantially not containing (-)-isomer.

4. The pharmaceutical according to claim 2 or claim 3, wherein 95 weight % or more of the total amount of the 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof in the pharmaceutical is (+)-isomer.

5. The pharmaceutical according to claim 4, wherein 98 weight % or more of the total amount of the 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof in the pharmaceutical is (+)-isomer.

6. The pharmaceutical according to claim 5, wherein 99.5 weight % or more of the total amount of the 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof in the pharmaceutical is (+)-isomer.

7. The pharmaceutical according to any one of claims 2 to 6, wherein the pharmaceutical is an external preparation.

8. The pharmaceutical according to claim 7, wherein the external preparation is selected from the group consisting of a lotion, cream, liquid and ointment.

9. The pharmaceutical according to claim 7 or 8, containing pharmaceutically acceptable glycols.

10. The pharmaceutical according to claim 9, wherein the pharmaceutically acceptable glycols is propylene glycol or butylene glycol.

11. The pharmaceutical according to any one of claims 7 to 10, containing water in the formulation.

12. The pharmaceutical according to any one of claims 7 to 11, containing as an active ingredient 1 w/w% or more (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.

13. The pharmaceutical according to claim 12, containing as an active ingredient 3 w/w% or more (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.

14. The pharmaceutical according to any one of claims 2 to 13, ~~being transdermally administered~~ for transdermal administration.

15. The pharmaceutical according to any one of claims 2 to 14, wherein the pharmaceutical is a preventive or treatement agent for a skin disease.

16. The pharmaceutical according to claim 15, wherein the skin disease is one or more selected from the group consisting of a localized scleroderma, atopic dermatitis, contact dermatitis,